TABLE 4 Clinical worsening events during CHEST-2
Former riociguatFormer placeboTotal
Subjects n15582237
Patients with clinical worsening#26 (17)12 (15)38 (16)
 PEA1 (1)1 (1)2 (1)
 Hospitalisation due to PH5 (3)1 (1)6 (3)
 Start of new PH treatment12 (8)7 (9)19 (8)
 Decrease in 6MWD due to PH2 (1)1 (1)3 (1)
 Persistent worsening of WHO FC due to PH5 (3)1 (1)6 (3)
 Death9 (6)4 (5)13 (5)
  • Data are presented as n (%), unless otherwise stated. The mean treatment duration was 83 weeks. PEA: pulmonary endarterectomy; PH: pulmonary hypertension; 6MWD: 6-min walking distance; WHO: World Health Organization; FC: functional class. #: one patient can experience more than one type of event.